SCHEMBL1187883

SCHEMBL1187883

CCCCCCCCCCCCCCCCCCCCCCCCc1cc(CC)cc(CCCCCCCCCCCCCCCCCCCCCCCC)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.61
CYP3A4 P08684 2/20 0.58
ESR1 P03372 2/20 0.56
ADRA2A P08913 2/20 0.56
ADORA3 P0DMS8 2/20 0.56
TACR2 P21452 2/20 0.56
SLC6A2 P23975 2/20 0.56
SLC6A4 P31645 2/20 0.56
SLC6A3 Q01959 2/20 0.56
KDM4E B2RXH2 1/20 0.56
ALDH1A1 P00352 1/20 0.56
LMNA P02545 1/20 0.56
SHBG P04278 1/20 0.56
TP53 P04637 1/20 0.56
HSPD1 P10809 1/20 0.56
ADRB3 P13945 1/20 0.56
HTR2C P28335 1/20 0.56
HSPE1 P61604 1/20 0.56
HIF1A Q16665 1/20 0.56
TST Q16762 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1187441 1.00 PTGS2 (0.61) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL1187357 1.00 PTGS2 (0.61) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL1188265 1.00 PTGS2 (0.61) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL1187238 1.00 PTGS2 (0.61) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL1186937 1.00 PTGS2 (0.61) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL1186501 1.00 PTGS2 (0.61) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL1187931 1.00 PTGS2 (0.61) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL1188932 1.00 PTGS2 (0.61) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL1186551 1.00 PTGS2 (0.61) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL1187824 1.00 PTGS2 (0.61) PTGS2CYP3A4ESR1ADRA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481736-B2 Liquid crystalline rylene tetracarboxylic acid derivatives and use thereof BASF SE (DE) 2013-07-09 US disclosed
US-20110042651-A1 LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF BASF SE (DE) 2011-02-24 US disclosed
EP-2008319-A2 LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF BASF SE (DE) 2008-12-31 EP disclosed
WO-2007116001-A2 LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF BASF SE (DE) 2007-10-18 WO disclosed
EP-1843407-A1 Liquid crystalline rylenetetracarboxylic acid derivatives and their use BASF AKTIENGESELLSCHAFT (DE) 2007-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110042651-A1 LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF TPR, ROR1, CA3 PTGS2 3500/4885CYP3A4 2295/4885ESR1 2855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.